WVE-007, a novel GalNAc-conjugated small interfering RNA (siRNA), is designed to silence INHBE messenger RNA, a genetically validated target for healthy weight loss that preserves muscle mass ...

Sirnaomics raised the money to advance a pipeline of drug candidates underpinned by its polypeptide nanoparticle (PNP) and GalNAc (N-Acetylgalactosamine) technology platforms (Fig. 1). PNP offers ...

RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...